SecBot SecBot
3 ·Filed Oct 8, 2026

NDRA

ENDRA Life Sciences Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed19d 3h ago SEC0001477932-26-006129
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

This is a routine Form 3 filing with no trading signal. Monitor for stockholder approval of the underlying shares, which would trigger exercisability of a large portion of the warrants and pre-funded warrants, potentially increasing dilution.

DirectionNeutral
Confidencehigh
Horizonmonths
Latest settled — T+5d ⚠ clustered
NDRA ▼ -13.19% at T+5d
NEUTRAL call -13.19% · α vs SPY -11.22% · entry $5.46 → $4.74
Next anchor: T+20d in 9d
Latest observation: T+10 -10.23% FF3 residual α
Entry = T+0 close
Oct 8, 2026
via day close
T+1d
-5.95%
call -5.95% · α -5.89%
$5.14
settled 18d ago
T+5d
-13.19%
call -13.19% · α -11.22%
$4.74
settled 12d ago
T+20d
Pending
in 9d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

ASP Isotopes Inc. and its wholly-owned subsidiary LHE LNG Holdings LLC filed Form 3 initial beneficial ownership statements for ENDRA Life Sciences Inc., disclosing aggregate holdings of 66,846 common shares, 511,541 pre-funded warrants, and 1,156,774 warrants exercisable at $6.57. The filing is a routine initial ownership disclosure with no material financial impact on ENDRA.

Key Facts

  • ASP Isotopes Inc. and LHE LNG Holdings LLC filed initial statements of beneficial ownership for ENDRA Life Sciences Inc.
  • LHE LNG holds 66,846 shares of ENDRA common stock.
  • LHE LNG holds pre-funded warrants to purchase up to 511,541 shares of common stock (187,169 exercisable within 60 days; 324,372 exercisable after stockholder approval).
  • LHE LNG holds warrants to purchase up to 1,156,774 shares of common stock at $6.57 per share, exercisable only after stockholder approval, expiring May 27, 2031.
  • ASP Isotopes controls LHE LNG and may be deemed to beneficially own the securities held by LHE LNG.

Financial Impact

No financial impact; initial ownership disclosure only.

Risk Factors

  • Future dilution risk if stockholder approval is obtained and warrants/pre-funded warrants are exercised.
  • No immediate catalyst from this filing.

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001477932-26-006129
Document: 0001477932-26-006129-index.html0001477932-26-006129
Document: 0001477932-26-006129.txt0001477932-26-006129
13 reports for NDRA
Performance horizon
50% Hit rate @ T+5 2 of 4 directional calls Went positive at some point 2 of 4 best @ T+60▲ +18.66%May 28, 2026
Filters
Rows
Reports for NDRA — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
425
NEUTRAL ★ 3/10
$4.82awaiting T+5—$4.96 (+2.93%)
Oct 8, 2026
19d ago
3
NEUTRAL ★ 2/10
$5.46 $4.74▼ −13.19%▼ −11.22%$4.96 (−9.14%)
Oct 8, 2026
19d ago
SC 13D
BULLISH ★ 7/10
$5.46 $4.74▼ −13.19%▼ −11.22%$4.96 (−9.14%)
Oct 1, 2026
26d ago
425
MIXED ★ 6/10
$6.06 $5.46▼ −9.90%▼ −11.06%$4.96 (−18.14%)
Oct 1, 2026
26d ago
8-K
NEUTRAL ★ 4/10
$6.06 $5.46▼ −9.90%▼ −11.06%$4.96 (−18.14%)
Sep 25, 2026
4w ago
425
NEUTRAL ★ 2/10
$5.80 $6.31▲ +8.79%▲ +7.59%$4.96 (−14.47%)
Sep 9, 2026
6w ago
425
NEUTRAL ★ 2/10
$5.83 $5.13▼ −12.01%▼ −11.67%$4.96 (−14.91%)
Aug 17, 2026
10w ago
8-K
NEUTRAL ★ 5/10
$4.51 $4.75▲ +5.32%▲ +5.52%$4.96 (+10.00%)
Jul 17, 2026
14w ago
425
NEUTRAL ★ 3/10
$4.99 $5.23▲ +4.81%▲ +5.50%$4.96 (−0.58%)
Jul 9, 2026
15w ago
8-K
NEUTRAL ★ 5/10
$5.49 $5.27▼ −4.01%▼ −3.88%$4.96 (−9.64%)
Showing 10 of 13

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 8, 2026